Insider-Trading
Aktuelle Insider-Transaktionen (SEC Form 4) — Käufe und Verkäufe von Vorständen, Direktoren und Großaktionären.
| Ticker | Insider | Funktion | Datum | Transaktion | Kurs ($) | Stück | Wert ($) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TARS | Link William J Phd | Director | 15.09.2026 | Verkauf | 80,01 | 66 | 5.281 | Form 4 |
| TARS | Link William J Phd | Director | 15.09.2026 | Verkauf | 79,00 | 759 | 59.961 | Form 4 |
| TARS | Link William J Phd | Director | 15.09.2026 | Verkauf | 78,33 | 11.675 | 914.503 | Form 4 |
| TARS | Link William J Phd | Director | 15.09.2026 | Optionsausübung | — | 201 | — | Form 4 |
| TARS | Yarno Wendy L | Director | 15.09.2026 | Optionsausübung | — | 302 | — | Form 4 |
| TARS | Pyott David E I | Director | 15.09.2026 | Optionsausübung | — | 201 | — | Form 4 |
| TARS | Lin Elizabeth Yeu | Chief Medical Officer | 04.09.2026 | Verkauf | 90,00 | 1.590 | 143.100 | Form 4 |
| TARS | Lin Elizabeth Yeu | Chief Medical Officer | 04.09.2026 | Verkauf | 90,00 | 5.386 | 484.740 | Form 4 |
| TARS | Lin Elizabeth Yeu | Chief Medical Officer | 04.09.2026 | Verkauf | 85,00 | 5.387 | 457.895 | Form 4 |
| TARS | Azamian Bobak R. | President/CEO and Board Chair | 04.09.2026 | Verkauf | 91,27 | 2.900 | 264.683 | Form 4 |
| TARS | Azamian Bobak R. | President/CEO and Board Chair | 04.09.2026 | Verkauf | 90,27 | 7.100 | 640.917 | Form 4 |
| TARS | Neervannan Seshadri | Chief Operating Officer | 04.09.2026 | Verkauf | 85,00 | 4.564 | 387.940 | Form 4 |
| TARS | Lin Elizabeth Yeu | Chief Medical Officer | 02.09.2026 | Verkauf | 80,00 | 1.590 | 127.200 | Form 4 |
| TARS | Lin Elizabeth Yeu | Chief Medical Officer | 02.09.2026 | Verkauf | 80,00 | 5.387 | 430.960 | Form 4 |
| TARS | Azamian Bobak R. | President/CEO and Board Chair | 02.09.2026 | Verkauf | 80,06 | 10.000 | 800.600 | Form 4 |
| TARS | Lin Elizabeth Yeu | Chief Medical Officer | 01.09.2026 | Verkauf | 73,86 | 4.601 | 339.830 | Form 4 |
Kompakter Markt-Überblick — keine Anlageberatung. Quelle: Fundamentaldaten & SEC-Berichte (Geschäfts- und Quartalsberichte, 10-K/10-Q).